Annual EBITDA
-$426.72 M
-$119.09 M-38.71%
December 31, 2024
Summary
- As of March 13, 2025, RXRX annual EBITDA is -$426.72 million, with the most recent change of -$119.09 million (-38.71%) on December 31, 2024.
- During the last 3 years, RXRX annual EBITDA has fallen by -$251.60 million (-143.67%).
- RXRX annual EBITDA is now -626.27% below its all-time high of -$58.76 million, reached on December 31, 2019.
Performance
RXRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$165.34 M
-$77.42 M-88.05%
December 31, 2024
Summary
- As of March 13, 2025, RXRX quarterly EBITDA is -$165.34 million, with the most recent change of -$77.42 million (-88.05%) on December 31, 2024.
- Over the past year, RXRX quarterly EBITDA has dropped by -$77.42 million (-88.05%).
- RXRX quarterly EBITDA is now -862.08% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$426.72 M
-$75.86 M-21.62%
December 31, 2024
Summary
- As of March 13, 2025, RXRX TTM EBITDA is -$426.72 million, with the most recent change of -$75.86 million (-21.62%) on December 31, 2024.
- Over the past year, RXRX TTM EBITDA has dropped by -$75.86 million (-21.62%).
- RXRX TTM EBITDA is now -2382.97% below its all-time high of -$17.19 million, reached on March 31, 2020.
Performance
RXRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RXRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.7% | -88.0% | -21.6% |
| 3 y3 years | -143.7% | -88.0% | -21.6% |
| 5 y5 years | -626.3% | -88.0% | -21.6% |
RXRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -143.7% | at low | -210.8% | at low | -143.7% | at low |
| 5 y | 5-year | -626.3% | at low | -862.1% | at low | -2383.0% | at low |
| alltime | all time | -626.3% | at low | -862.1% | at low | -2383.0% | at low |
Recursion Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$426.72 M(+38.7%) | -$165.34 M(+88.1%) | -$426.72 M(+21.6%) |
| Sep 2024 | - | -$87.92 M(-0.9%) | -$350.86 M(+0.7%) |
| Jun 2024 | - | -$88.70 M(+4.7%) | -$348.35 M(+5.3%) |
| Mar 2024 | - | -$84.75 M(-5.3%) | -$330.81 M(+7.5%) |
| Dec 2023 | -$307.63 M(+35.1%) | -$89.48 M(+4.8%) | -$307.63 M(+12.9%) |
| Sep 2023 | - | -$85.41 M(+20.0%) | -$272.42 M(+11.4%) |
| Jun 2023 | - | -$71.16 M(+15.6%) | -$244.45 M(+3.6%) |
| Mar 2023 | - | -$61.58 M(+13.5%) | -$236.05 M(+3.7%) |
| Dec 2022 | -$227.66 M | -$54.27 M(-5.5%) | -$227.67 M(-3.6%) |
| Sep 2022 | - | -$57.44 M(-8.5%) | -$236.12 M(+5.7%) |
| Jun 2022 | - | -$62.76 M(+18.0%) | -$223.45 M(+12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$53.20 M(-15.2%) | -$199.25 M(+13.8%) |
| Dec 2021 | -$175.12 M(+114.3%) | -$62.72 M(+40.1%) | -$175.12 M(+28.0%) |
| Sep 2021 | - | -$44.77 M(+16.1%) | -$136.82 M(+19.3%) |
| Jun 2021 | - | -$38.57 M(+32.7%) | -$114.66 M(+22.5%) |
| Mar 2021 | - | -$29.07 M(+19.1%) | -$93.58 M(+14.5%) |
| Dec 2020 | -$81.70 M(+39.1%) | - | - |
| Dec 2020 | - | -$24.41 M(+7.9%) | -$81.70 M(+42.6%) |
| Sep 2020 | - | -$22.61 M(+29.3%) | -$57.29 M(+65.2%) |
| Jun 2020 | - | -$17.49 M(+1.8%) | -$34.68 M(+101.8%) |
| Mar 2020 | - | -$17.19 M | -$17.19 M |
| Dec 2019 | -$58.76 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual EBITDA year-on-year change?
- What is Recursion Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Recursion Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM EBITDA year-on-year change?
What is Recursion Pharmaceuticals annual EBITDA?
The current annual EBITDA of RXRX is -$426.72 M
What is the all time high annual EBITDA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual EBITDA is -$58.76 M
What is Recursion Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, RXRX annual EBITDA has changed by -$119.09 M (-38.71%)
What is Recursion Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of RXRX is -$165.34 M
What is the all time high quarterly EBITDA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly EBITDA is -$17.19 M
What is Recursion Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, RXRX quarterly EBITDA has changed by -$77.42 M (-88.05%)
What is Recursion Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of RXRX is -$426.72 M
What is the all time high TTM EBITDA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM EBITDA is -$17.19 M
What is Recursion Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, RXRX TTM EBITDA has changed by -$75.86 M (-21.62%)